INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma

Phase 2 Terminated 8 enrolled Incyte Corporation

Non-randomizedCrossoverOpen-labelTreatment

Summary

A Phase 2, open-label study to evaluate the safety and efficacy of INCB040093 as monotherapy and as combination therapy with itacitinib (INCB039110) in subjects with relapsed or refractory Hodgkin Lymphoma.

Timeline

Start: 2015-06
Primary completion: 2016-12-16
Completion: 2016-12-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	INCB040093	Unknown	—	Oral
Subject	Itacitinib	Small molecule	—	Oral

INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma

Summary

Timeline

Drugs

Indications